RxDoctor Payments Data

Opal Thakar, MD

Family Medicine · Long Branch, NJNPI 1659792802

Payments from drug & device makers

$5,684in general payments, 2019–2025

Across 371 payments — averaging $15.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$768
  • AstraZeneca$711
  • GSK$386
  • Exact Sciences$344
  • Merck$306
  • plus $2K from 24 others

What the payments were for

  • Food & beverage$5,684100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,684 in reported general payments places this provider in the 90th percentile of 2,084 family medicine providers in New Jersey.

See all family medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$63,963
Medicare patients
248
Services billed
574

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide70$83,973
JanuviaSitagliptin Phosphate30$32,399
Janumet XrSitagliptin Phos/Metformin Hcl44$31,897
EliquisApixaban70$30,962
JanumetSitagliptin Phos/Metformin Hcl19$23,171
FarxigaDapagliflozin Propanediol17$21,587
Humalog Kwikpen U-200Insulin Lispro18$9,137
Victoza 2-PakLiraglutide13$7,490
XareltoRivaroxaban12$7,406
Bromocriptine Mesylate12$5,842
Esomeprazole Magnesium15$3,310
Lantus SolostarInsulin Glargine,hum.Rec.Anlog21$2,425
Atorvastatin Calcium219$2,183
Omega-3 Acid Ethyl Esters23$2,162
Levothyroxine Sodium138$1,795

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet Xr, Janumet$306$87,46893 claims
Novo NordiskOzempic$1,368$83,97370 claims
PfizerEliquis$247$30,96270 claims
AstraZenecaFarxiga$711$21,58717 claims
Johnson & JohnsonXarelto$11$7,40612 claims
AbbVieSynthroid$768$87318 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,084 family medicine providers in New Jersey.

Other family medicine in Long Branch

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →